BridgeBio Pharma Intangible Assets

BridgeBio Pharma's intangible assets stands at $27M as of March 2026. That compares with $28M in the prior-year period — down 1.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

BridgeBio Pharma reported $27M in intangible assets versus $28M a year earlier — a 1.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $28M in the prior-year period — down 1.6% year over year. Sustained growth in intangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how BridgeBio Pharma's intangible assets evolved across reporting periods, while the comparison chart places BBIO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, intangible assets is commonly used to spot outliers. BridgeBio Pharma's reading of $27M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.